Clinical use of Cryoprecipitate
- Arthur J Silvergleid, MD
Arthur J Silvergleid, MD
- Section Editor — Transfusion Medicine
- Affiliate Associate Professor, Department of Pathology and Cell Biology
- University of South Florida, College of Medicine
- Medical Director, OneBlood, Inc.
Cryoprecipitate (Cryoprecipitated antihemophilic factor [AHF]; cryo) is the insoluble material that comes out of solution after plasma is frozen and thawed at 4°C (between 1 and 6°C). It is rich in certain plasma proteins, especially fibrinogen.
This topic will discuss the clinical use of Cryoprecipitate. Use of other plasma products and plasma derivatives is discussed in separate topic reviews:
●Fresh Frozen Plasma (FFP) and other plasma products – (See "Clinical use of plasma components".)
●Plasma derivatives including coagulation factor concentrates – (See "Plasma derivatives and recombinant DNA-produced coagulation factors".)
●Fibrin sealant – (See "Fibrin sealants".)To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126:11.
- Callum JL, Karkouti K, Lin Y. Cryoprecipitate: the current state of knowledge. Transfus Med Rev 2009; 23:177.
- Hesselvik F, Brodin B, Carlsson C, et al. Cryoprecipitate infusion fails to improve organ function in septic shock. Crit Care Med 1987; 15:475.
- Infusion rate
- Dosing interval
- CLINICAL USES
- Overview of uses
- Inherited disorders of fibrinogen
- Impaired hemostasis in liver disease
- Disseminated intravascular coagulation
- Uremic bleeding
- CONDITIONS FOR WHICH CRYOPRECIPITATE IS INEFFECTIVE
- RISKS AND ADVERSE EVENTS
- SUMMARY AND RECOMMENDATIONS